Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Cecilia BrownAcute Myeloid Leukemia | March 23, 2023
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
Read More
Cecilia BrownAcute Myeloid Leukemia | March 23, 2023
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Cecilia BrownAcute Myeloid Leukemia | March 21, 2023
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Cecilia BrownAcute Myeloid Leukemia | March 21, 2023
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
Leah SherwoodAcute Myeloid Leukemia | March 1, 2023
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
Cecilia BrownAcute Myeloid Leukemia | February 24, 2023
A multivariate analysis identified 11 "consistent independent adverse factors" associated with survival.
Advertisement
Cecilia BrownMeeting News | February 24, 2023
The Clever-1 targeting antibody is currently under evaluation in clinical trials as part of a combination therapy.
Cecilia BrownMeeting News | February 22, 2023
Mitochondrial targeting strategies could be combined with chemotherapy as part of induction and consolidation for AML.
Leah SherwoodAcute Myeloid Leukemia | February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Cecilia BrownAcute Myeloid Leukemia | February 17, 2023
Data from a recent preclinical study “support combining ERK1/2 and BCL-2 inhibitors” in the treatment of AML.
Leah SherwoodAcute Myeloid Leukemia | February 13, 2023
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
Leah SherwoodAcute Myeloid Leukemia | February 13, 2023
These results have potential implications for the long-term success of venetoclax therapy.
Leah SherwoodAcute Myeloid Leukemia | February 8, 2023
The study also found DDX41 germline variants explained approximately 80% of known germline predisposition to MNs in adults.
Cecilia BrownAcute Myeloid Leukemia | February 7, 2023
Combining proteomic data with genetic risk-stratification data may help tailor therapy for pediatric AML.
Leah SherwoodAcute Myeloid Leukemia | February 7, 2023
Maintenance therapy strategies for AML have been investigated for decades, including single agents and combinations.
Cecilia BrownAcute Myeloid Leukemia | January 26, 2023
A participant’s death led to a voluntary pause of a phase I/II trial evaluating MGTA-117 in relapsed/refractory AML and ...
Leah SherwoodAcute Myeloid Leukemia | January 23, 2023
The U.S. Food and Drug Administration has granted Orphan Drug Designation for JBI-802 for the treatment of AML.
Cecilia BrownAcute Myeloid Leukemia | January 17, 2023
A phase III trial of enasidenib in patients with IDH2-mutated AML failed to meet its primary endpoint.
Cecilia BrownAcute Myeloid Leukemia | January 3, 2023
Vemurafenib retreatment may be a “safe and effective option” for patients with relapsed/refractory hairy cell leukemia.
Cecilia BrownAcute Myeloid Leukemia | January 3, 2023
Venetoclax plus gilteritinib is a “potentially active regimen” in patients with high-risk wild-type FLT3 AML.
Advertisement
Advertisement
Editorial Board